Skip to main content

Semaglutide vs Teriparatide

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

Semaglutide

Semaglutide is a GLP-1 receptor agonist — a 31-amino acid peptide analog of human glucagon-like peptide-1 (GLP-1) with a 94% sequence homology to native GLP-1. It is FDA-approved for type 2 diabetes (Ozempic, Rybelsus) and chronic weight management (Wegovy). Semaglutide has an albumin-binding fatty acid side chain that extends its half-life to approximately 7 days, enabling once-weekly dosing. It is the most widely prescribed GLP-1 medication globally, with over 25 million Americans expected to be on GLP-1 therapy by 2030.

Full details →

Teriparatide

Teriparatide (Forteo) is recombinant human parathyroid hormone (1-34), FDA-approved for osteoporosis treatment. It's unique among osteoporosis drugs in that it stimulates new bone formation.

Full details →

Side-by-Side Comparison

AspectSemaglutideTeriparatide
MechanismSemaglutide binds to and activates the GLP-1 receptor, a G-protein coupled receptor expressed in pancreatic beta cells, the hypothalamus, and the gastrointestinal tract. This triggers multiple downstream effects: (1) glucose-dependent insulin secretion from pancreatic beta cells, (2) suppression of glucagon release from alpha cells, (3) delayed gastric emptying, slowing nutrient absorption, (4) central appetite suppression via hypothalamic GLP-1 receptors, reducing hunger and increasing satiety. The peptide features a C-18 fatty diacid moiety attached via a linker to Lys26, enabling non-covalent albumin binding that protects against DPP-4 degradation and renal clearance.Intermittent PTH exposure paradoxically stimulates osteoblasts more than osteoclasts, resulting in net bone formation. Continuous exposure would cause bone loss, but pulsatile dosing builds bone.
Typical DosageFor weight management (Wegovy): start at 0.25 mg weekly for 4 weeks, escalate to 0.5 mg, 1.0 mg, 1.7 mg, and finally 2.4 mg weekly. Each escalation lasts 4 weeks. Maintenance dose is 2.4 mg weekly. For type 2 diabetes (Ozempic): start at 0.25 mg weekly for 4 weeks, increase to 0.5 mg. May increase to 1 mg, then 2 mg if additional glycemic control is needed. Oral semaglutide (Rybelsus): 3 mg daily for 30 days, then 7 mg daily. May increase to 14 mg daily. Oral Wegovy: 3 mg daily for 4 weeks, escalate to 7 mg, 14 mg, and 25 mg daily. Take on empty stomach with no more than 4 oz of water, 30 minutes before food.20mcg subcutaneously once daily. Maximum treatment duration of 2 years due to theoretical osteosarcoma risk from rat studies.
AdministrationInjectable: subcutaneous injection in the abdomen, thigh, or upper arm. Rotate injection sites. Store pens refrigerated (36-46°F) before first use; after first use, store at room temperature or refrigerated for up to 56 days. Oral: take on an empty stomach with a sip of plain water (no more than 4 oz). Wait at least 30 minutes before eating, drinking, or taking other oral medications. Do not split, crush, or chew tablets.Subcutaneous injection in thigh or abdomen once daily. Delivered via multi-dose pen. Should sit or lie down after injection due to orthostatic hypotension risk.
Side EffectsVery common (>10%): nausea (up to 44%), diarrhea, vomiting, constipation, abdominal pain. These are typically mild-to-moderate and decrease over time with dose escalation. Common (1-10%): headache, fatigue, dyspepsia, dizziness, bloating, flatulence, GERD, gastroenteritis. Notable: 'Ozempic face' (facial volume loss due to rapid weight loss), hair loss (telogen effluvium, reported in 25-33% of users in some studies), injection site reactions.Orthostatic hypotension, leg cramps, nausea, dizziness, headache, and injection site reactions. Transient hypercalcemia possible.
Best For

Key Differences

Detailed Analysis

Commonalities

Semaglutide and Teriparatide are used for different purposes and have limited overlap in their applications.

Which Should You Choose?

Choose Semaglutide for Fat Loss, Gut Health. Choose Teriparatide for Recovery & Healing.

Ready to Learn More?